Medicinova, Inc.
MNOVMedicinnova, Inc. is a biotechnology company focused on developing novel therapeutics for rare and serious diseases. The company's research primarily targets conditions with limited treatment options, leveraging its expertise in drug discovery and development to bring innovative solutions to unmet medical needs.
Company News
The alcohol use disorder (AUD) market is projected to grow at a 12.1% CAGR from 2026-2036, driven by novel therapeutic mechanisms and new drug approvals. The market was valued at USD 1.1 billion in 2025 across seven major markets. Key emerging therapies from companies like Adial Pharmaceuticals, Eli Lilly, MediciNova, and Altimmune are expected t...
MediciNova announced the completion of the last patient last visit (LPLV) in its Phase 2 clinical trial (MN-001-NATG-202) evaluating MN-001 (tipelukast) for treating hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes. The randomized, double-blind, placebo-controlled trial enrolled patients receiving either 5...
A peer-reviewed study published in Cancer Research by Spanish National Cancer Research Centre (CNIO) identifies macrophage migration inhibitory factor (MIF)-mediated reprogramming as a central vulnerability in brain metastasis. The research demonstrates that MediciNova's lead compound MN-166 (ibudilast) can effectively block MIF-CD74 signaling an...
MediciNova announced that President and CEO Yuichi Iwaki and Chief Business Officer David H. Crean will participate in the 38th Annual ROTH Conference on March 22-24, 2026 in Dana Point, California. The executives will host one-on-one and small group meetings with investors to provide company updates on their clinical-stage biopharmaceutical pipe...
MediciNova announced that 100 patients have been enrolled in the SEANOBI expanded-access program evaluating MN-166 (ibudilast) for ALS treatment, representing 50% of the planned 200-patient enrollment across 12 US sites. The program is funded by a $22 million NIH/NINDS grant. MN-166 is also being evaluated in the COMBAT-ALS Phase 2b/3 trial with ...
